Clinical Pharmacokinetics of Tirofiban, a Nonpeptide Glycoprotein IIb/IIIa Receptor Antagonist: Comparison with the Monoclonal Antibody Abciximab

Author： Kondo K.   Umemura K.  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.41, Iss.3, 2002-01, pp. : 187-195

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tirofiban:an investigational plateletglycoprotein IIb/IIIa receptor antagonist

By Kumar A.   Herrmann H.C.  

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 9, 1997-09 ,pp. : 1247-1256

Informa Healthcare

Access to resources Recommend Favorite

Abciximab (Reopro): a clinically effective glycoprotein IIb/IIIa receptor blocker

By de Belder M.   Sutton A.  

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 10, 1998-10 ,pp. : 1701-1717

Informa Healthcare

Access to resources Recommend Favorite

Glycoprotein IIb/IIIa Receptor Antagonists: Clinical Pharmacology in Cardiovascular Diseases of Aging

By Sebastian M.   Makkar R.  

Drugs & Aging, Vol. 15, Iss. 3, 1999-09 ,pp. : 207-218

Adis International

Access to resources Recommend Favorite

Platelet inhibition by abciximab is reduced in patients with the A2 allele of the glycoprotein (GP) IIb/IIIa receptor

By  

Inpharma, Vol. 1, Iss. 1328, 2002-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Platelet glycoprotein IIb/IIIa receptor antagonists

By Casserly I.P.   Moliterno D.J.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 419-433

Informa Healthcare

Access to resources Recommend Favorite